Simplex Trading
APLS

Simplex Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Simplex Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Sell
6,800
-37,500
-85% -$808K ﹤0.01% 3923
2025
Q4 		$1.11M Sell
44,300
-100
-0.2% -$2.35K ﹤0.01% 2527
2025
Q3 		$1M Buy
44,400
+5,700
+15% +$133K ﹤0.01% 3042
2025
Q2 		$669K Sell
38,700
-9,800
-20% -$181K ﹤0.01% 3200
2025
Q1 		$1.06M Buy
48,500
+5,300
+12% +$146K ﹤0.01% 2657
2024
Q4 		$1.38M Sell
43,200
-61,300
-59% -$1.84M ﹤0.01% 2542
2024
Q3 		$3.01M Buy
104,500
+51,100
+96% +$1.89M ﹤0.01% 1917
2024
Q2 		$2.05M Sell
53,400
-15,300
-22% -$693K ﹤0.01% 2182
2024
Q1 		$4.04M Sell
68,700
-48,100
-41% -$3.07M ﹤0.01% 1769
2023
Q4 		$6.99M Sell
116,800
-106,900
-48% -$5.42M ﹤0.01% 1329
2023
Q3 		$8.51M Buy
223,700
+23,200
+12% +$1.02M 0.01% 1005
2023
Q2 		$18.3M Buy
200,500
+93,000
+87% +$8.02M 0.02% 624
2023
Q1 		$7.09M Buy
107,500
+45,700
+74% +$2.64M 0.01% 1082
2022
Q4 		$3.19M Sell
61,800
-3,900
-6% -$207K ﹤0.01% 1517
2022
Q3 		$4.49M Buy
65,700
+47,700
+265% +$2.82M 0.01% 1275
2022
Q2 		$813K Sell
18,000
-17,000
-49% -$775K ﹤0.01% 2854
2022
Q1 		$1.78M Buy
35,000
+32,000
+1,067% +$1.41M ﹤0.01% 2231
2021
Q4 		$141K Sell
3,000
-2,100
-41% -$82.7K ﹤0.01% 5695
2021
Q3 		$345K Buy
5,100
+100
+2% +$5.62K ﹤0.01% 4683
2021
Q2 		$316K Buy
5,000
+4,923
+6,394% +$254K ﹤0.01% 4884
2021
Q1 		$330K Buy
+77
New +$3.64K ﹤0.01% 4022
2020
Q3 		– Sell
-166
Closed -$542K – 7733
2020
Q2 		$542K Sell
166
-190
-53% -$6.1K ﹤0.01% 2793
2020
Q1 		$953K Buy
356
+145
+69% +$5.15K ﹤0.01% 1928
2019
Q4 		$646K Buy
211
+191
+955% +$5.29K ﹤0.01% 2494
2019
Q3 		$48K Buy
+20
New +$550 ﹤0.01% 5047

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Simplex Trading's APLS Position: Q1 2026 in Review

Simplex Trading reduced its Apellis Pharmaceuticals (APLS) stake by 90% in Q1 2026, selling an estimated $527K and leaving 2,735 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #4966.

Simplex Trading first reported a position in APLS in Q2 2019 and has held it in 19 quarters since. The position peaked at $6.92M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Simplex Trading held 2,735 shares of Apellis Pharmaceuticals worth $110K as of Q1 2026.
  • Simplex Trading sold 24,452 Apellis Pharmaceuticals shares in Q1 2026, an estimated $527K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4966 holding.
  • Simplex Trading first reported a position in Apellis Pharmaceuticals in Q2 2019 and has held it in 19 quarters since.
  • Simplex Trading's Apellis Pharmaceuticals position peaked at $6.92M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.